Friday - November 21, 2025

Ocumension Therapeutics Highlights Global Myopia Burden and Regulatory Progress in Low-Dose Atropine Therapies

Low-dose atropine has emerged as a promising option to help reduce long-term complications. Ocumension Therapeutics (Shanghai) Co., Ltd today shared an update on the global landscape of pediatric myopia treatment, emphasizing the growing unmet need for clinically meaningful interventions and … Continue reading